DENOSUMAB VERSUS ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES SECONDARY TO SOLID TUMOURS: AN INTEGRATED ANALYSIS OF THREE PHASE 3 STUDIES

被引：1
|
作者：
Stopeck, A. T. [1 ]
Richardson, G. [2 ]
Siena, S. [3 ]
Lipton, A. [4 ]
Brown, J. [5 ]
Fizazi, K. [6 ]
Henry, D. [7 ]
Saad, F. [8 ]
Ke, C. [9 ]
Braun, A. [9 ]
机构：
[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA
[2] Cabrini Hosp, Malvern, Vic, Australia
[3] Osped Niguarda Ca Granda, Milan, Italy
[4] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA
[5] Canc Res, UK Clin Ctr, Leeds, W Yorkshire, England
[6] Univ Paris 11, Inst Gustave Roussy, Villejuif, France
[7] Joan Karnell Canc Ctr, Philadelphia, PA USA
[8] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada
[9] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/j.ejca.2012.02.030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [1] Denosumab In the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumours
    Scott, Lesley J.
    Muir, Victoria J.
    DRUGS, 2011, 71 (08) : 1059 - 1069
  • [2] A COMPARISON OF DENOSUMAB VERSUS ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN BREAST CANCER PATIENTS WITH BONE METASTASES
    Fujiwara, Yasuhiro
    Stopeck, Alison
    de Boer, Richard
    Lichinitser, Mikhail
    Tonkin, Katia
    Yardley, Denise
    Fan, Michelle
    Jiang, Qi
    Jun, Susie
    Dansey, Roger
    Braun, Ada
    ANNALS OF ONCOLOGY, 2010, 21 : 12 - 12
  • [3] A Comparison of Denosumab Versus Zoledronic Acid for the Prevention of Skeletal-Related Events in Breast Cancer Patients with Bone Metastases
    Stopeck, A.
    de Boer, R.
    Fujiwara, Y.
    Lichinitser, M.
    Tonkin, K.
    Yardley, D.
    Fan, M.
    Jiang, Q.
    Jun, S.
    Dansey, R.
    Braun, A.
    CANCER RESEARCH, 2009, 69 (24) : 490S - 490S
  • [4] Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics
    Lipton, A.
    Fizazi, K.
    Stopeck, A. T.
    Henry, D. H.
    Smith, M. R.
    Shore, N.
    Martin, M.
    Vadhan-Raj, S.
    Brown, J. E.
    Richardson, G. E.
    Saad, F.
    Yardley, D. A.
    Zhou, K.
    Balakumaran, A.
    Braun, A.
    EUROPEAN JOURNAL OF CANCER, 2016, 53 : 75 - 83
  • [5] The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials
    Zhang, Zhicai
    Pu, Feifei
    Shao, Zengwu
    JOURNAL OF BONE ONCOLOGY, 2017, 9 : 21 - 24
  • [6] COMPARATIVE BUDGET IMPACT OF FORMULARY INCLUSION OF ZOLEDRONIC ACID AND DENOSUMAB FOR PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES
    Bell, M. J.
    Miller, J. D.
    Namjoshi, M.
    Russell, M. W.
    VALUE IN HEALTH, 2011, 14 (03) : A159 - A159
  • [7] NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours
    Jilani, Anwar
    Garrett, Zoe
    Sutcliffe, Frances
    Stevens, Andrew
    LANCET ONCOLOGY, 2012, 13 (12): : 1194 - 1195
  • [8] COST-EFFECTIVENESS OF DENOSUMAB VERSUS ZOLEDRONIC ACID (ZA) FOR THE PREVENTION OF SKELETAL-RELATED EVENTS (SRE) IN PATIENTS WITH BONE METASTASES FROM SOLID TUMORS IN THE NETHERLANDS
    Lothgren, M.
    Bracco, A.
    Lucius, B.
    Northridge, K.
    Halperin, M.
    Macarios, D.
    Chung, K.
    Danese, M. D.
    VALUE IN HEALTH, 2011, 14 (07) : A455 - A455
  • [9] DenosumabIn the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumours
    Lesley J. Scott
    Victoria J. Muir
    Drugs, 2011, 71 : 1059 - 1069
  • [10] Denosumab in the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid TumorsProfile Report
    Lesley J. Scott
    Victoria J. Muir
    BioDrugs, 2011, 25 : 397 - 400
12345